复星医药(600196.SH):HLX55用于无其他标准治疗的晚期实体瘤治疗临床试验获批
格隆汇9月4日丨复星医药(600196.SH)公布,近日,公司控股子公司汉霖生技股份有限公司(设立于中国台湾地区,系公司控股子公司上海复宏汉霖生物技术股份有限公司之控股子公司;“汉霖生技”)收到台湾“卫生福利部”关于其原则同意HLX55(“该新药”)用于无其他标准治疗的晚期实体瘤治疗临床试验的函(发文字号:卫授食字第1086019441号)。汉霖生技拟于近期条件具备后于中国台湾地区开展针对该适应症的I期临床试验。
该新药为集团获Kolltan Pharmaceuticals, Inc.许可、并后续自主研发的创新型治疗用生物制品,主要用于转移性或复发性实体瘤的治疗。
截至公告日,在全球范围内尚无与该新药同类产品上市。
截至2019年7月,集团现阶段针对该新药累计研发投入为人民币约6122万元(未经审计;包括许可费)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.